Innovation Pipeline: Examining Modern Medicine
August 1, 2017
San Francisco
With changing technological advances as part of its DNA, San Francisco is turning its attention to medicine. As it does, ideas sourced by nearby talent pools and ample venture capital investment will strengthen the innovation pipeline bringing about new breakthroughs in medicine.
In the third event of the “Examining Modern Medicine” series, The Atlantic gathered stakeholders, original thinkers and trailblazers from the nation’s innovation capital to explore what it means to put the bio into biotech. Where is the industry headed and what are the moonshots coming out of the Bay Area that could change the world of medicine?
Watch full session videos
Presented by
Speakers
-
![Robert Califf]()
Robert Califf Advisor, Verily Life Sciences; Professor of Medicine, Duke University; Former FDA Commissioner @calif001 -
![Leon Chen]()
Leon Chen Venture Partner OrbiMed Advisors @OrbiMed -
![Christina Farr]()
Christina Farr Health and Technology Reporter CNBC @chrissyfarr -
![Carol Gallagher]()
Carol Gallagher Partner NEA @carol_gallagher -
![Cary Gunn]()
Cary Gunn CEO and Founder Genalyte @Genalyte -
![Sean Harper]()
Sean Harper Executive Vice President, Research and Development Amgen @Amgen -
![Regis Kelly, OBE]()
Regis Kelly, OBE Executive Director, QB3; Byers Family Distinguished Professor, UCSF @QB3 -
![Ron Leuty*]()
Ron Leuty* Reporter San Francisco Business Times @rleuty_biotech -
![Nils Lonberg*]()
Nils Lonberg* Senior Vice President, Oncology Discovery Biology Bristol-Myers Squibb @bmsnews -
![Gabriel Otte]()
Gabriel Otte CEO and Co-Founder Freenome @GabeOtte -
![Sara Radcliffe]()
Sara Radcliffe President and CEO California Life Sciences Association @CALifeSciences -
![Andrew Schiff]()
Andrew Schiff Managing Partner Aisling Capital -
![Lynn Seely]()
Lynn Seely President and CEO Myovant Sciences -
![Harold "Barry" Selick]()
Harold "Barry" Selick Vice Chancellor Business Development, Innovation and Partnerships UCSF @UCSFOTM -
![Robin Thurston]()
Robin Thurston CEO Helix @RobinJThurston -
![Steve Clemons]()
Steve Clemons Washington Editor at Large, The Atlantic @SCClemons -
![Alexis Madrigal]()
Alexis Madrigal Staff Writer The Atlantic @alexismadrigal
Agenda
- Tuesday, August 01
- 8:30 a.m.WelcomeMargaret Low, President, AtlanticLIVE
- 8:35 a.m.The Innovation LandscapeRegis Kelly, OBE, Executive Director, QB3; Byers Family Distinguished Professor, UCSF
Sara Radcliffe, President and CEO, California Life Sciences Association
Harold Selick, Vice Chancellor, Business Development, Innovation and Partnerships, UCSF
With Alexis Madrigal, Staff Writer, The Atlantic - 9:05 a.m.Putting the Bio in Biotech: The Challenges and Future of Biopharmaceuticals* Nils Lonberg, Senior Vice President, Oncology Discovery Biology, Bristol-Myers Squibb
With Ron Leuty, Biotech Reporter, San Francisco Business Times - 9:15 a.m.Making a Bet on BiotechLeon Chen, Venture Partner, OrbiMed
Carol Gallagher, Partner, New Enterprise Associates Inc.
Andrew Schiff, ManagingPartner, Aisling Capital
With Steve Clemons, Washington Editor at Large, The Atlantic - 9:45 a.m.The Biotech PlayersCary Gunn, CEO and Founder, Genalyte
Sean Harper, Executive Vice President, Research and Development, Amgen
Gabe Otte, CEO and Co-Founder, Freenome
Lynn Seely, CEO, Myovant Sciences
With Alexis Madrigal, The Atlantic - 10:15 a.m.What Consumers WantRobin Thurston, CEO, Helix
With Christina Farr, Health and Technology Reporter, CNBC - 10:35 a.m.The Marriage of Big Data and HealthRobert Califf, Advisor, Verily Life Sciences; Professor of Medicine, Duke University; Former Commissioner, FDA
With Steve Clemons, The Atlantic - 11:00 a.m.Closing ThoughtsMargaret Low, AtlanticLIVE
